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able learning curve, resulting in an undersizing or oversizing or the
incomplete piercing of the saphenous vein, followed by rolling up
of the intima and resulting thereby in graft stenosis or occlusion,
mechanical alteration of the intima itself, or bioincompatibility of
the device. The significance of the ACS in the genesis of proximal
graft stenosis, thrombosis, or both has to be elucidated by means of
further investigations.
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In September 1996 a 31-year-old man was admitted to PaduaHospital, Padua, Italy, in cardiogenic shock that was notresponsive to medical treatment and intra-aortic balloonpump insertion. The patient had Castleman disease, and in
1989 he was treated with cycles of cyclophosphamide, vincristine,
mitoxantrone hydrochloride (INN: mitoxantrone), and interferon.
In June 1996 at another hospital, he had postchemotherapy dilated
cardiomyopathy diagnosed, with akinesia of septum and anterior
left ventricle wall (end-diastolic volume 230 mL, end-systolic
volume 180 mL, ejection fraction 20%, and left ventricular end-
diastolic diameter 67 mm). Because of severe left ventricular
failure, we started therapy with a BioMedicus left ventricular assist
device (Medtronic BioMedicus, Inc, Minneapolis, Minn) and an
intra-aortic balloon pump. In October 1996 we converted the
centrifugal pump support to a Novacor left ventricular assist sys-
tem (World Heart Novacor LVAS N100 PCq; World Heart Cor-
poration, Ottawa, Ontario, Canada) because of the impossibility of
weaning the patient from the BioMedicus pump and the risks
associated with heart transplantation related to potential relapse of
neoplastic disease (chest computed tomographic scan with medi-
astinal lymph nodes  2 cm).
The Novacor left ventricular assist system, a device used for
patients with cardiogenic shock, is considered an interim system to
be used before transplantation or to achieve left ventricular recov-
ery for patients who are not candidates for transplantation.1 In the
long term the main disadvantages of this device are driveline
infections, thromboembolism, and system failures affecting the
pump and valves.2
During the patient’s recovery period, he had several episodes of
pocket driveline infections and one episode of cerebral embolism,
all with complete recovery (no abnormal findings on cerebral
computed tomographic scan at follow-up). After the patient had
been supported by the Novacor device for 24 months, we at-
tempted to wean him from the system but were unable to do so. In
June 2000, the patient showed moderate dyspnea with symptoms
of congestive heart failure that necessitated angiotensin-converting
enzyme inhibitors and diuretics. A 2-dimensional Doppler echo-
cardiographic evaluation showed moderate incompetence of the
Novacor inflow valve. After 50 months of successful mechanical
circulatory support (December 5, 2000), there were no signs indi-
cating a relapse of Castleman disease, and we were able to perform
orthotopic heart transplantation.
As a result of chemotherapy for Castleman disease, this patient
had marked variations in myocardial cells, as seen in the endo-
myocardial biopsy specimen, with great areas of interstitial fibrosis
that caused left ventricular dysfunction. Because of the possibility
of myocardial function recovery and the high rate of neoplastic
lesions seen in other transplant recipients after immunosuppressive
therapy,3 rather than perform an orthotopic heart transplant we
supported the patient with a mechanical Novacor device. With the
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initial acute phase overcome but without satisfactory midterm
heart function recovery, the Novacor device allowed us to support
the patient for a total of 1512 days. During this phase the patient
had an acceptable quality of life and was out of the hospital for a
total of 1280 days (Figure 1). To date this patient’s experience with
the mechanical circulatory support system has been the longest
reported worldwide. After a 4-year period without any recurrence
of neoplastic lesions, we were able to perform a successful heart
transplant procedure.
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Figure 1. Patient shown at 32 years old at work with the Novacor left ventricular assist device slung over his right
shoulder (left) and at 37 years old after orthotopic heart transplantation (right).
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